Teladoc Health, Inc. (NYSE:TDOC – Get Rating) SVP Daniel Trencher sold 1,000 shares of Teladoc Health stock in a transaction that occurred on Friday, June 17th. The stock was sold at an average price of $29.12, for a total value of $29,120.00. Following the completion of the transaction, the senior vice president now directly owns 28,408 shares in the company, valued at $827,240.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of TDOC traded up $0.84 during trading hours on Tuesday, hitting $31.51. 3,995,137 shares of the stock traded hands, compared to its average volume of 6,461,438. The company has a current ratio of 3.94, a quick ratio of 3.71 and a debt-to-equity ratio of 0.17. Teladoc Health, Inc. has a 1-year low of $27.38 and a 1-year high of $174.32. The firm has a market capitalization of $5.08 billion, a PE ratio of -0.75 and a beta of 0.81. The business has a fifty day moving average of $39.97 and a 200-day moving average of $63.75.
More automakers are pledging to go “fully electric” by 2035. NOW is the perfect time to get in on the “EV Revolution.” And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks…
Teladoc Health (NYSE:TDOC – Get Rating) last issued its quarterly earnings results on Wednesday, April 27th. The health services provider reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.08. Teladoc Health had a negative return on equity of 2.12% and a negative net margin of 321.94%. The business had revenue of $565.35 million for the quarter, compared to analyst estimates of $568.91 million. During the same quarter in the prior year, the firm posted $0.13 earnings per share. As a group, equities research analysts expect that Teladoc Health, Inc. will post -2.05 earnings per share for the current fiscal year.
TDOC has been the topic of several recent analyst reports. StockNews.com initiated coverage on Teladoc Health in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. Piper Sandler lifted their price target on Teladoc Health from $21.00 to $42.00 in a research report on Friday, May 13th. Citigroup downgraded Teladoc Health from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $115.00 to $43.00 in a research report on Thursday, April 28th. Deutsche Bank Aktiengesellschaft dropped their price target on Teladoc Health from $78.00 to $44.00 in a research report on Thursday, April 28th. Finally, Wells Fargo & Company downgraded Teladoc Health from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $104.00 to $40.00 in a research report on Thursday, April 28th. One analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $88.36.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Future Financial Wealth Managment LLC bought a new stake in Teladoc Health in the fourth quarter valued at about $29,000. CarsonAllaria Wealth Management Ltd. bought a new stake in Teladoc Health in the fourth quarter valued at about $30,000. DB Wealth Management Group LLC bought a new stake in Teladoc Health in the first quarter valued at about $25,000. McCarthy Asset Management Inc. bought a new stake in Teladoc Health in the first quarter valued at about $25,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new stake in Teladoc Health in the first quarter valued at about $27,000. Institutional investors and hedge funds own 87.17% of the company’s stock.
About Teladoc Health (Get Rating)
Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Teladoc Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Teladoc Health wasn’t on the list.
While Teladoc Health currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.